Recent developments surrounding the 340B program reveal ongoing tensions between drug manufacturers and healthcare providers. Missouri Attorney General Catherine Hanaway has ordered Eli Lilly to cease its demands for 340B claims data. This follows a lawsuit filed by five Massachusetts hospitals against the company for cutting off 340B discounts due to similar data refusals. The American Hospital Association has expressed support for the SUSTAIN 340B Act and called for revisions to its provisions. Concurrently, the PROTECT 340B Act has been introduced to address the exploitation of the program by pharmacy benefit managers and insurers. An HHS report has criticized the program’s expansion, suggesting a shift towards profit over patient care, further complicating the situation for covered entities reliant on 340B discounts.
Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter to Eli Lilly, demanding an end to its 340B claims data requirement.
Five Massachusetts hospitals filed a lawsuit against Eli Lilly for unlawfully cutting off 340B discounts over claims data refusal.
The AHA supports the SUSTAIN 340B Act but seeks changes to several provisions in a letter to its sponsors.
Reps. Matsui and Mann introduced the PROTECT 340B Act to prevent PBM and insurer exploitation of the 340B program.
An HHS report states the 340B program has expanded beyond its original intent, prioritizing hospital profit over patient care.
Drugmakers, including AbbVie and PhRMA, filed motions to intervene in a lawsuit challenging HRSA’s 340B Rebate Model Pilot Program.
The SUSTAIN 340B Act seeks to establish clear rules for the 340B program, including contract pharmacy use and data clearinghouse.
A new bill proposes delaying the 340B Rebate Model Pilot for two years, requiring upfront discounts instead.
- Hospitals face potential loss of 340B discounts if unable to comply with data demands.
- Drugmakers may face increased legal challenges over 340B policies.
- Legislative changes could alter 340B program rules, impacting hospital operations.
- Non-compliance with new rules could result in financial penalties for PBMs and insurers.
- Changes in reimbursement rates may affect hospital revenue streams.
- Hospitals can use legislative support to strengthen 340B program participation.
- New bills may provide clearer guidelines and protections for covered entities.
- Potential for improved negotiation positions with drug manufacturers.
- Opportunity to influence policy through active engagement with lawmakers.
- Hospitals can improve compliance strategies to meet new transparency requirements.
- Hospitals should review and adapt to new 340B compliance requirements.
- Engage with lawmakers to support favorable 340B legislation.
- Monitor legal developments in 340B-related lawsuits.
- Prepare for potential changes in reimbursement models and financial impacts.
- Strengthen internal data management systems to meet transparency demands.
- Missouri AG Catherine Hanaway issued a cease-and-desist letter to Eli Lilly.
- The letter demands an end to claims data requirements for 340B discounts.
- Failure to comply may lead to enforcement action under state law.
- Five Massachusetts hospitals filed a lawsuit against Eli Lilly.
- The lawsuit challenges Eli Lilly’s demand for patient claims data.
- Hospitals allege violations of Massachusetts’ consumer protection law.
- The AHA supports the SUSTAIN 340B Act.
- The Act aims to codify rules for the 340B program.
- AHA requested changes to several provisions in a letter to sponsors.
- Reps. Matsui and Mann introduced the PROTECT 340B Act.
- The Act aims to prevent PBM and insurer exploitation of the 340B program.
- It includes provisions for a third-party clearinghouse and civil penalties.
- HHS report states 340B program prioritizes hospital profit over patient care.
- The report cites growth in program participation and costs.
- Hospitals oppose rebate models, citing cash-flow and administrative burdens.
- New bill proposes delaying the 340B Rebate Model Pilot for two years.
- The delay would require upfront discounts instead of rebates.
- The bill aims to give Congress time for broader 340B reform.
| Court | Matter | Date |
|---|---|---|
| D. Mass. | Massachusetts hospitals v. Eli Lilly, claims data dispute. [source] | October 27, 2026 |
| D. Me. | American Hospital Association v. Kennedy, drugmakers seek intervention. [source] | October 16, 2026 |
| Manufacturer | Action | Date |
|---|---|---|
| Eli Lilly | Sued by Massachusetts hospitals for 340B data demands. [source] | October 27, 2026 |
- HRSA’s 340B Rebate Model Pilot Program to begin January 2027. [source]
- Potential legislative action on the PROTECT 340B Act. [source]
- Missouri AG’s deadline for Eli Lilly to end 340B data policy by November 26. [source]
- Congressional review of the SUSTAIN 340B Act provisions. [source]
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.